Authors

Feng Yuan*, Chen Sining*, Zhou Ying**, Xia Ze***, Lin Weinan*, Zhu Lin*, Song Shenge*,Wei Lulu*, Li Jianzhe****, Tang Fangmei*****, Jiang Ying******,#

Departments

*Department of Respiratory Medicine - **Department of Radiation Oncology - ***Department of Party office - ***Department of Pharmacy - *****Department of Clinical Laboratory - ******Department of Neurology, Ruikang Hospital affiliated to Guangxi University of Traditional Chinese Medicine, Nanning 530011, Guangxi, China

Abstract

Objective: To explore the clinical efficacy and safety of Bufei Huayu Decoction combined with gefitinib in the treatment of advanced non-small cell lung cancer. 

Methods: 130 patients with advanced non-small cell lung cancer, who were diagnosed and treated in our hospital from January 2014 to June 2015, were enrolled in this study. These patients were randomly divided into observation group (n=65) and control group (n=65). The patients in the control group were administered gefitinib for 30 days. The patients in the observation group were administered Bufei Huayu Decoction besides gefitinib for 30 days. The clinical efficacy, coagulation indexes, prognostic difference and incidence of adverse drug reactions were compared before and after treatment in the two groups.  

Results: The total response rate (92.31% vs 76.92%; χ2=5.909, P=0.015) and clinical benefit rate (95.38% vs 83.02%; χ2=5.123, P=0.024) were significantly higher in the observation group than those in the control group. There was no significant difference in coagulation indexes between the two groups before treatment (P>0.05). After treatment, PT, APTT, FIB, D-D, and PLT were significantly lower in the observation group than those in the control group (P<0.05). However, MPV and PDW were significantly higher in the observation group than those in the control group (P<0.05). Thrombosis risk (HR=0.3471, 95%CI[0.1376, 0.8756], P=0.028), mortality risk (HR=0.5664, 95%CI[0.3319, 0.9664], P=0.044), and disease progression risk (HR=0.5363, 95%CI[0.3365, 0.8549], P=0.027) were significantly lower in the observation group than in the control group. The incidence of skin rash and ALT level were significantly lower in the observation group than those in the control group after treatment (P<0.05). 

Conclusions: Bufei Huayu Decoction combined with gefitinib in the treatment of advanced non-small cell lung cancer has a significant effect, can effectively regulate coagulation dysfunction, reduce the risk of thrombosis, improve the long-term prognosis of patients, and has good safety. 

Keywords

Bufei Huayu Decoction, gefitinib, non-small cell lung cancer, coagulation dysfunction, prognosis.

DOI:

10.19193/0393-6384_2020_3_285